At what enterprise value was DECHRA PHARMACEUTICALS acquired in 2023?

During the acquisition of DECHRA PHARMACEUTICALS by EQT PARTNERS / ADIA in 2023, the company was valued at an estimated revenue multiple of 5x - 12x. The transaction's Enterprise Value is estimated to be in the range of 3b - 100b GBP. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of DECHRA PHARMACEUTICALS when it was acquired by EQT PARTNERS / ADIA?

The estimated EV/EBITDA multiple for DECHRA PHARMACEUTICALS is in the range of Above 20x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was DECHRA PHARMACEUTICALS acquired by EQT PARTNERS / ADIA?

DECHRA PHARMACEUTICALS was acquired by EQT PARTNERS / ADIA in 2023.

What was the revenue of DECHRA PHARMACEUTICALS at the time of the deal?

The revenue of DECHRA PHARMACEUTICALS at the time of the deal is estimated to be in the range of 450M - 900M GBP. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of DECHRA PHARMACEUTICALS during the acquisition?

DECHRA PHARMACEUTICALS's EBITDA is estimated to be in the range of 100M - 200M GBP. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the DECHRA PHARMACEUTICALS acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DECHRA PHARMACEUTICALS deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.reuters.com/business/healthcare-pharmaceuticals/eqt-take-uks-dechra-pharma-private-about-6-bln-deal-2023-06-02/#:~:text=June%202%20(Reuters)%20%2D%20Swedish,veterinary%20drugmaker%20said%20on%20Friday.

← DATABASE

Home Database Healthcare & PharmaDECHRA PHARMACEUTICALS

07/2023

DECHRA PHARMACEUTICALS acquired by EQT PARTNERS & ADIA

UNITED KINGDOM Life Sciences / Pharma & Biotech EV 3b - 100b GBP

Context

EQT completed the take-private acquisition of Dechra Pharmaceuticals. The strategic rationale for taking Dechra private was to support its long-term growth away from the volatility of public markets. In early 2023, Dechra faced headwinds from "wholesaler de-stocking" in the US, which hit its share price. EQT intends to accelerate investment in the company's innovation pipeline and support further international acquisitions without the pressure of quarterly earnings reporting.

DECHRA PHARMACEUTICALS, which reported an EBITDA margin of LOGIN in 2023, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Headquartered in Northwich, UK, Dechra is a global specialist in veterinary pharmaceuticals. Unlike animal health giants that focus on livestock vaccines, Dechra carved out a high-margin niche in "specialist" treatments for companion animals (dogs, cats, horses). It is a world leader in veterinary endocrinology (treating diseases like Cushing's in dogs) and topical dermatology.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (GBP)

Year

Rev

EBITDA

EBIT

2023

2022

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
08/2023	CARL ZEISS MEDITEC	D.O.R.C. (DUTCH OPHTHALMIC RESEARCH CENTER)	NETHERLANDS	Life Sciences	Eurazeo has completed the sale of D.O.R.C. to Carl Zeiss Meditec AG. This transaction marks the successful conclusion of a four-year transformation under Eurazeo's ownership, during which D.O.R.C. evolved from a European champion into a global platform
08/2023	ATHOS CONSORTIUM	SCHÜLKE	GERMANY	Life Sciences	EQT Private Equity has agreed to sell 100% of Schülke to a consortium led by ATHOS, following a highly successful three-year transformation period. EQT originally acquired the company in a 2020 carve-out from Air Liquide for approximately €1
07/2023	LAUXERA	ORGANOX	UNITED KINGDOM	Life Sciences	Lauxera Capital Partners has successfully led a £25 million growth investment into OrganOx, marking a pivotal minority platform entry into the high-barrier medical technology sector. Based in Oxford, England, the commercial-stage enterprise represents a strategic addition to the investor's specialized healthcare portfolio
07/2023	ELOS MEDTECH	KLINGEL MEDICAL GROUP	GERMANY	Life Sciences	Elos Medtech entered into an agreement to acquire 100% of Klingel Medical Group from IK Partners and its management team. The strategic rationale for the deal is to create a market-leading European MedTech CDMO with significantly enhanced R&D capabilities and a broader technological offering
06/2023	NOVO NORDISK	BIOCORP	FRANCE	Life Sciences	The acquisition of Biocorp by Novo Nordisk, achieved through the purchase of Bio Jag's 45.3% stake and a subsequent mandatory public tender offer, marks a significant shift in strategy, transitioning from a collaborative research and development model to a proprietary technology platform
04/2023	HALMA	APRIOMED	SWEDEN	Life Sciences	The successful acquisition of AprioMed by IZI Medical Products represents a tactical expansion of Halma’s healthcare portfolio in the interventional radiology segment. This transaction marks the integration of AprioMed’s highly specialized bone biopsy technology, effectively widening the technical operational depth available to IZI Medical’s global clinical customer base
04/2023	SARTORIUS	POLYPLUS	France	Life Sciences	Sartorius Stedim Biotech has reached a definitive agreement to acquire one hundred percent of the share capital of Polyplus from private equity sponsors ArchiMed and Warburg Pincus. This landmark transaction is structured as a full buyout, effectively transferring ownership from financial sponsors to a strategic corporate acquirer
02/2023	ARDIAN	THERADIAL	FRANCE	Life Sciences	Ardian has acquired a stake in Théradial, a specialized player in the French dialysis sector, with a consolidated presence in medical product distribution, pharmaceuticals, and healthcare software. This transaction is part of a strategic partnership with UI Investissement, which had previously invested in the company in 2017
10/2022	STANLEY CAPITAL PARTNERS	LABORATOIRE X.O	FRANCE	Life Sciences	Stanley Capital Partners acquired a majority stake in Laboratoire X.O following the liquidation of its former owner, Novalpina Capital. The deal resolved a year-long legal dispute between management and transitional managers (BRG)
10/2022	IK PARTNERS	UNITHER	FRANCE	Life Sciences	Unither Pharmaceuticals, a global leader in sterile single-unit dosage manufacturing, has undergone a capital reorganization led by its management team and a consortium of prominent investors. GIC and IK Partners have entered as new equity partners, while Keensight Capital and Parquest are reinvesting to reinforce their existing positions

REFERENCES

Valuation range: EV 3b - 100b GBP

Revenue range: 450M - 900M GBP

EBITDA range: 100M - 200M GBP

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DECHRA PHARMACEUTICALS by EQT PARTNERS / ADIA are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: dechra pharmaceuticals

Acquirer: eqt partners / adia